BUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'

Reuters

Nov 15, 2024

BUZZ-Leerink Partners cuts Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to 'market perform'

** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to "market perform" from "outperform," cuts PT to $4 from $5

** Cites "uncertainties" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine

** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared

** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate

** Six of seven analysts rate CMPX stock "buy" or higher and one "hold"; their median PT is $7.50 - LSEG

** As of last close, CMPX stock has risen 1.9% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2483114374"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2483114374\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2483114374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483114374","market":"us","top_or_hot":-1,"title":"BUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Leerink Partners cuts Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to 'market perform'</title></head><body>** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to \"market perform\" from \"outperform,\" cuts PT to $4 from $5** Cites \"uncertainties\" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine ** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared ** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate** Six of seven analysts rate CMPX stock \"buy\" or higher and one \"hold\"; their median PT is $7.50 - LSEG** As of last close, CMPX stock has risen 1.9% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2024-11-15 22:27\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Leerink Partners cuts Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to 'market perform'</title></head><body>** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to \"market perform\" from \"outperform,\" cuts PT to $4 from $5** Cites \"uncertainties\" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine ** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared ** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate** Six of seven analysts rate CMPX stock \"buy\" or higher and one \"hold\"; their median PT is $7.50 - LSEG** As of last close, CMPX stock has risen 1.9% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPX","symbol_name":"Compass Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4N3MM0YR:1","article_id":"2483114374","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483114374","pubTimestamp":1731680859,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to \"market perform\" from \"outperform,\" cuts PT to $4 from $5** Cites \"uncertainties\" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine ** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared ** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate** Six of seven analysts rate CMPX stock \"buy\" or higher and one \"hold\"; their median PT is $7.50 - LSEG** As of last close, CMPX stock has risen 1.9% YTD ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPX":"Compass Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Leerink Partners将Compass Therapeutics评级下调至“市场表现”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":0.9},"content_text":"BUZZ-Leerink Partners cuts Compass Therapeutics to 'market perform'** Brokerage Leerink Partners downgrades drug developer Compass Therapeutics CMPX.O to \"market perform\" from \"outperform,\" cuts PT to $4 from $5** Cites \"uncertainties\" in CMPX's experimental drug, CTX-009, developed for colorectal cancer that affects the large intestine ** Brokerage says it is disappointed by the drug's 5% response rate in Western patients, compared with 33% in South Korean ones; response rate refers to the proportion of patients whose tumors shrank or disappeared ** Leerink says the drug also needs to show a benefit for patient survival, apart from a favorable response rate** Six of seven analysts rate CMPX stock \"buy\" or higher and one \"hold\"; their median PT is $7.50 - LSEG** As of last close, CMPX stock has risen 1.9% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}